CRCT stock shows bearish sentiment due to consistent insider selling, including the CEO's recent sale of 21,250 shares, and no insider purchases in the last six months. Institutional activity is mixed, with more additions than reductions, but the stock's price target was recently lowered by Goldman Sachs from $6.5 to $5.75, reflecting cautious outlook. These factors suggest limited upside potential in the near term.